Blank Bio Closes $7.2M Seed Financing And Strategic Collaboration With Pacific Biosciences

Collaboration with PacBio will generate long-read bulk RNA-seq data to advance patient-level prediction from tumor transcriptomes

Blank Bio, an applied AI research lab training foundation models for RNA, today announced the closing of a $7.2 million seed financing and a strategic collaboration with Pacific Biosciences (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions. Blank Bio is building RNA foundation models that learn directly from the molecular complexity of tumor transcriptomes to improve patient-level prediction across oncology. Proceeds from the financing will support continued model development, expanded collaborations with pharmaceutical and diagnostic companies, and new long-read RNA-seq datasets to support applications in biomarkers, clinical trial design, and diagnostics.